Replies to post #32879 on Endonovo Therapeutics Inc (ENDV)

[Biotech_Tradez]

ENDV's real business is selling stock.

$2K per month in sales is pathetic.

I always look at what they hide in the notes:

Note 11 – Subsequent Events

Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.”

Subsequent to March 31, 2023, the Company issued 350,000 shares of common stock for services.

Subsequent to March 31, 2023, the Company issued 1,000,000 shares of common stock pursuant to an independent consulting agreement.

Subsequent to March 31, 2023, the Company issued 1 unit or 5,000,000 shares of common stock pursuant to a private placement for total net cash receipt of $46,000.

Subsequent to March 31,2023, the Board of director approved the issuance of 39,150,000 shares of common stock for past services.

Subsequent to March 31, 2023, the Company issued 1,667,000 shares of common stock pursuant to a settlement of an account payable.

Subsequent to March 31, 2023, the Company issued 350,000 shares of common stock in conjunction with promissory totaling $50,000.

Subsequent to March 31, 2023, the Company granted 3,000,000 stock options to purchase 3,000,000 shares of common shares vesting over 3 years at an exercise price of $0.012 per share for consulting services.

I wonder who Collier gave 39 million shares to? That is 13% of the company and should have been put out in an 8K and a Form 3 filed. This guy is a straight con man.